These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34398956)

  • 1. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
    Kendall MA; Lalloo U; Fletcher CV; Wu X; Podany AT; Cardoso SW; Ive P; Benson CA
    Clin Infect Dis; 2021 Aug; 73(4):706-715. PubMed ID: 34398956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.
    Kouanda S; Ouedraogo HG; Cisse K; Compaoré TR; Sulis G; Diagbouga S; Roggi A; Tarnagda G; Villani P; Sangare L; Simporé J; Regazzi M; Matteelli A
    BMC Infect Dis; 2020 Jun; 20(1):449. PubMed ID: 32590942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.
    Ouedraogo HG; Matteelli A; Sulis G; Compaore TR; Diagbouga S; Tiendrebeogo S; Roggi A; Cisse K; Giorgetti PF; Villani P; Sangare L; Simpore J; Regazzi M; Kouanda S
    Ann Clin Microbiol Antimicrob; 2020 Jan; 19(1):3. PubMed ID: 31969147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
    Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H
    PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
    Naiker S; Connolly C; Wiesner L; Kellerman T; Reddy T; Harries A; McIlleron H; Lienhardt C; Pym A
    BMC Pharmacol Toxicol; 2014 Nov; 15():61. PubMed ID: 25406657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change.
    Jacobs TG; Mumbiro V; Chitsamatanga M; Namuziya N; Passanduca A; Domínguez-Rodríguez S; Tagarro A; Nathoo KJ; Nduna B; Ballesteros A; Madrid L; Mujuru HA; Chabala C; Buck WC; Rojo P; Burger DM; Moraleda C; Colbers A; ;
    J Acquir Immune Defic Syndr; 2023 May; 93(1):42-46. PubMed ID: 36724434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy.
    Semere Gebreyesus M; Wasmann RE; McIlleron H; Oladokun R; Okonkwo P; Wiesner L; Denti P; Rawizza HE
    Antimicrob Agents Chemother; 2024 Aug; 68(8):e0035424. PubMed ID: 39037240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis.
    Boulanger C; Rolla V; Al-Shaer MH; Peloquin C
    Int J Antimicrob Agents; 2020 Feb; 55(2):105840. PubMed ID: 31704214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
    Lan NT; Thu NT; Barrail-Tran A; Duc NH; Lan NN; Laureillard D; Lien TT; Borand L; Quillet C; Connolly C; Lagarde D; Pym A; Lienhardt C; Dung NH; Taburet AM; Harries AD
    PLoS One; 2014; 9(1):e84866. PubMed ID: 24465443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoption of evidence-informed guidelines in prescribing protease inhibitors for HIV-Tuberculosis co-infected patients on rifampicin and effects on HIV treatment outcomes in Uganda.
    Mulindwa F; Castelnuovo B; Kirenga B; Kalibbala D; Haguma P; Muddu M; Semitala FC
    BMC Infect Dis; 2021 Aug; 21(1):822. PubMed ID: 34399706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients.
    Ramachandran G; Hemanth Kumar AK; Kannan T; Sridhar R; Guha SK; Kadam D; Poorana Gangadevi N; Rajapandian T
    Indian J Tuberc; 2019 Jan; 66(1):129-133. PubMed ID: 30797270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.
    Decloedt EH; Maartens G; Smith P; Merry C; Bango F; McIlleron H
    PLoS One; 2012; 7(3):e32173. PubMed ID: 22412856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.
    Ofotokun I; Sheth AN; Sanford SE; Easley KA; Shenvi N; White K; Eaton ME; Del Rio C; Lennox JL
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1196-206. PubMed ID: 22364141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
    Martin A; Moore CL; Mallon PW; Hoy JF; Emery S; Belloso WH; Phanuphak P; Ferret S; Cooper DA; Boyd MA;
    PLoS One; 2013; 8(10):e77138. PubMed ID: 24204757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa.
    Sunpath H; Winternheimer P; Cohen S; Tennant I; Chelin N; Gandhi RT; Murphy RA
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):689-93. PubMed ID: 24903940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex.
    Le X; Guo X; Sun J; Liu L; Shen Y; Wang J; Qi T; Wang Z; Tang Y; Song W; Yin L; Zhang L; Zhang R; Chen J
    Int J Infect Dis; 2022 Mar; 116():147-150. PubMed ID: 34999246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.
    Moultrie H; McIlleron H; Sawry S; Kellermann T; Wiesner L; Kindra G; Gous H; Van Rie A
    J Antimicrob Chemother; 2015 Feb; 70(2):543-9. PubMed ID: 25281400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
    Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K;
    Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.